Médecine

Paramédical

Autres domaines


S'abonner

Hair disorders in patients with cancer - 12/04/19

Doi : 10.1016/j.jaad.2018.03.055 
Azael Freites-Martinez, MD a, Jerry Shapiro, MD b, Shari Goldfarb, MD c, Julie Nangia, MD d, Joaquin J. Jimenez, MD e, f, Ralf Paus, MD, FRSB g, h, i, Mario E. Lacouture, MD a,
a Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 
c Breast Cancer Medicine Service, Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 
b The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York 
d Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas 
e Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida 
f Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, Florida 
g Dermatology Research Centre, University of Manchester, Manchester, United Kingdom 
h National Institute of Health Research Manchester Biomedical Research Centre, Manchester, United Kingdom 
i Department of Dermatology, University of Munster, Munster, Germany 

Correspondence to: Mario E. Lacouture, MD, Dermatology Service, Memorial Sloan Kettering Cancer Center, 60th St Outpatient Center, Ste 407, Rm 4312, 16 E 60th St, New York, NY 10022.Dermatology ServiceMemorial Sloan Kettering Cancer Center60th St Outpatient Center, Ste 407, Rm 4312, 16 E 60th StNew YorkNY10022

Abstract

Cytotoxic chemotherapies, molecularly targeted therapies, immunotherapies, radiotherapy, stem cell transplants, and endocrine therapies may lead to hair disorders, including alopecia, hirsutism, hypertrichosis, and pigmentary and textural hair changes. The mechanisms underlying these changes are varied and remain incompletely understood, hampering the development of preventive or therapeutic guidelines. The psychosocial impact of chemotherapy-induced alopecia has been well documented primarily in the oncology literature; however, the effect of other alterations, such as radiation-induced alopecia, hirsutism, and changes in hair color or texture on quality of life have not been described. This article reviews clinically significant therapy-related hair disorders in oncology patients, including the underlying pathophysiological mechanisms, severity grading scales, patient-reported quality of life questionnaires, management strategies, and future translational research opportunities.

Le texte complet de cet article est disponible en PDF.

Key words : anagen effluvium, brittleness, cancer patients, catagen effluvium, chemotherapy-induced alopecia, curling, depigmentation, eyebrow alopecia, eyelash alopecia, hair repigmentation, hirsutism, hyperpigmentation, hypertrichosis, hypopigmentation, straightening, trichomegaly

Abbreviations used : AE, CIA, CTCAE v5.0, EGFR, MKI, QoL, RIA


Plan


 Supported in part by National Institutes of Health/National Cancer Institute Cancer Center support grant P30 CA008748. Dr Lacouture is supported by the RJR Oncodermatology Fund. Dr Freites-Martinez is partially supported by Beca Excelencia, Academia Española de Dermatología y Venereología–Fundación Piel Sana. Dr Paus is supported by the National Institute of Health Research Manchester Biomedical Research Centre.
 Dr Shapiro has been a consultant for Aclaris, Samumed, Incyte, Replicel Life Sciences, and Shook, Hardy, and Bacon LLP, who represent Sanofi Aventis US LLC. Dr Goldfarb has a speaking, consultant, or advisory role with Adgero Biopharmaceuticals, AMAG Pharmaceuticals, Procter and Gamble, and Valeant women's health pharmaceuticals. Dr Nangia received clinical trial funding from Paxman to the Baylor College of Medicine for conduct of the SCALP trial. Dr Paus has a consultant role with or receives research funding from Giuliani/Italy and Unilever/UK, and is founder/owner of Monasterium Laboratory/Germany. Dr Lacouture has a speaking, consultant, or advisory role with Abbvie, Quintiles, Boehringer Ingelheim, AstraZeneca Pharmaceuticals, Legacy Healthcare, Foamix, Adgero Bio Pharmaceuticals, Janssen R&D, Novartis, Paxman, and Novocure, and also receives research grants from Berg and Bristol-Myers Squibb. Drs Freites-Martinez and Jimenez have no conflicts of interest to disclose.
 Date of release: May 2019
 Expiration date: May 2022


© 2018  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 80 - N° 5

P. 1179-1196 - mai 2019 Retour au numéro
Article précédent Article précédent
  • Journal Based CME Instructions and Information
| Article suivant Article suivant
  • CME examination

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement ou un achat à l’unité.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.